Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moderate-to-severe atopic dermatitis.
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moderate-to-severe atopic dermatitis.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Practical Dermatology: Atopic Dermatitis
Understanding Disparities in AD
<p>Understanding Disparities in AD</p>
Practical Dermatology: Atopic Dermatitis
New Drugs Helping AD Catch Up to Psoriasis
<p>New Drugs Helping AD Catch Up to Psoriasis</p>
Practical Dermatology: Atopic Dermatitis
Addressing the Unique Challenges of AD Patients
<p>Addressing the Unique Challenges of AD Patients </p>
Practical Dermatology: Atopic Dermatitis
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
<p>FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)</p>
Practical Dermatology: Atopic Dermatitis
NIH Analysis Examines Association Between AD and Comorbidities
<p>NIH Analysis Examines Association Between AD and Comorbidities</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?